<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01625949</url>
  </required_header>
  <id_info>
    <org_study_id>ICMR project 80/3/2010-BMS</org_study_id>
    <secondary_id>I-676</secondary_id>
    <nct_id>NCT01625949</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy in Patients With Myocardial Infarction and Persistent Total Occlusion of Infarct Related Artery</brief_title>
  <acronym>COAT</acronym>
  <official_title>Study of Stem Cell Therapy in Patients With Myocardial Infarction and Persistent Total Occlusion of Infarct Related Artery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indian Council of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>All India Institute of Medical Sciences, New Delhi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: When an acute myocardial infarction occurs, the artery supplying the infarct zone
      should be opened within twenty four hours of onset of infarction. This has clearly been shown
      to be beneficial.

      If the patient presents later than 24 hours of onset, at that stage a large part of the
      damage to the heart is irreversible. Intervening at this stage (beyond 24 hours is
      controversial). Some trials suggest that opening the artery even at this stage positively
      modifies the remodeling process while other trials suggest that such a benefit is not seen.

      Hypothesis: Opening an infarct related artery after 24 hours (until 6 months) and combining
      it with intracoronary stem cell therapy may provide incremental benefit.It is possible that
      the lack of benefit seen with late revascularization (&gt;24 hrs) after MI may be offset by
      giving intracoronary stem cells after opening the artery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives

      The benefit of opening an infarct related artery after the period of myocardial salvage (In
      patients who do not come to medical attention within 24 hrs of an infarctions) has been
      questioned in recent trials. On the other hand, Stem cell therapy after myocardial infarction
      has been shown to improve myocardial function both in the acute and chronic phases. It is
      possible that the lack of benefit seen with late revascularization (&gt;24 hrs) after MI may be
      offset by giving intracoronary stem cells after opening the artery. Patients with recent
      myocardial infarction (MI) and occluded infarct related arteries supplying a large myocardial
      territory and with reduced ejection fraction will be randomized to a percutaneous coronary
      intervention (PCI) arm and a PCI plus stem cell arm .

      The objective of the trial is to demonstrate that opening an infarct related artery after 24
      hours and before six months and following it with intracoronary stem cell therapy may provide
      incremental benefit.

      The primary objective

      To demonstrate benefits in left ventricular recovery (improvement in function by
      echocardiogram and Nuclear imaging: Multigated acquisition [MUGA], reduction in scar size by
      tetrofosmin scan/Positron Emission Tomography[PET]. )

      The secondary objectives

      To demonstrate improvement in functional capacity as assessed by 6 minute walk test and
      quality of life assessment, along with reduction of first occurrence of recurrent MI,
      hospitalization/treatment of New York Heart Association class IV congestive heart failure, or
      death
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>left ventricular function</measure>
    <time_frame>3 Months</time_frame>
    <description>Change in left ventricular function (assessed by Nuclear imaging and ECHO) and change in myocardial viability [assessed by PET].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in functional capacity</measure>
    <time_frame>3 months</time_frame>
    <description>change in functional capacity as assessed by 6 minute walk test, quality of life assessment, first occurrence of recurrent MI,</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Control Arm (Standard Therapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Arm Receiving The Standard Therapy including successful coronary intervention and stenting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intracoronary stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intracoronary stem cells injection</intervention_name>
    <description>Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting autologous bone marrow stem cells from iliac crest 60 ml bone marrow will be extracted and purified for mononuclear cells which will be injected.</description>
    <arm_group_label>Intracoronary stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>coronary dilatation and stenting</intervention_name>
    <description>coronary dilatation and stenting</description>
    <arm_group_label>Control Arm (Standard Therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:18 to 80 years

          2. Sex:Both

          3. Recent MI (3-28 d)

          4. Obstructed artery needing intervention

          5. consent for stem cell therapy

        Exclusion Criteria:

          1. Left main disease or Triple vessel disease[TVD] needing surgery

          2. Hypotension

          3. Consent not given
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandeep Seth, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Balram Airan, DM</last_name>
    <role>Study Chair</role>
    <affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>V K Bahl, DM</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Balram Bhargava, DM</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chetan Patel</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sujata Mohanty</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajiv Narang, DM</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS., New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S Ramakrishnan, DM</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS. New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K C Goswami, DM</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rakesh Yadav, DM</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ambuj Roy, DM</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G Karthikeyan, DM</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gautam Sharma, DM</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandeep Singh, DM</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandeep Mishra, DM</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nitish Naik, DM</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS, New Delhi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandeep Seth, DM</last_name>
    <phone>91-11-26594970</phone>
    <email>aiimscardiology@yahoo.co.in</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>S Seth</last_name>
    <email>drsandeepseth@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep Seth, DM</last_name>
      <phone>91-11-26594970</phone>
      <phone_ext>4970</phone_ext>
      <email>aiimscardiology@yahoo.co.in</email>
    </contact>
    <contact_backup>
      <last_name>S Seth</last_name>
      <email>drsandeepseth@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sandeep Seth, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Strauer BE, Brehm M, Zeus T, Bartsch T, Schannwell C, Antke C, Sorg RV, Kögler G, Wernet P, Müller HW, Köstering M. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J Am Coll Cardiol. 2005 Nov 1;46(9):1651-8.</citation>
    <PMID>16256864</PMID>
  </reference>
  <reference>
    <citation>Menasché P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L, Vilquin JT, Marolleau JP, Seymour B, Larghero J, Lake S, Chatellier G, Solomon S, Desnos M, Hagège AA. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation. 2008 Mar 4;117(9):1189-200. doi: 10.1161/CIRCULATIONAHA.107.734103. Epub 2008 Feb 19.</citation>
    <PMID>18285565</PMID>
  </reference>
  <reference>
    <citation>Dib N, Michler RE, Pagani FD, Wright S, Kereiakes DJ, Lengerich R, Binkley P, Buchele D, Anand I, Swingen C, Di Carli MF, Thomas JD, Jaber WA, Opie SR, Campbell A, McCarthy P, Yeager M, Dilsizian V, Griffith BP, Korn R, Kreuger SK, Ghazoul M, MacLellan WR, Fonarow G, Eisen HJ, Dinsmore J, Diethrich E. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation. 2005 Sep 20;112(12):1748-55.</citation>
    <PMID>16172284</PMID>
  </reference>
  <reference>
    <citation>Assmus B, Fischer-Rasokat U, Honold J, Seeger FH, Fichtlscherer S, Tonn T, Seifried E, Schächinger V, Dimmeler S, Zeiher AM; TOPCARE-CHD Registry. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry. Circ Res. 2007 Apr 27;100(8):1234-41. Epub 2007 Mar 22.</citation>
    <PMID>17379833</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2012</study_first_submitted>
  <study_first_submitted_qc>June 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2012</study_first_posted>
  <last_update_submitted>June 22, 2012</last_update_submitted>
  <last_update_submitted_qc>June 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, New Delhi</investigator_affiliation>
    <investigator_full_name>Dr Sandeep Seth</investigator_full_name>
    <investigator_title>Additional Professor, Department of Cardiology</investigator_title>
  </responsible_party>
  <keyword>myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

